ArticleThe Laryngoscope2026
Feasibility of Awake In-Office Transnasal Double Balloon Dilation of the Pharyngoesophageal Segment.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesTo review experience with and describe the feasibility of unsedated in-office transnasal double balloon dilations of the pharyngoesophageal segment (PES).
methodsAdults who underwent office-based transnasal double balloon dilations of the PES at a single academic institution over a 3-year period were retrospectively studied. Clinicodemographic data, prior PES dilation history, procedural indications, pre-procedure anxiolytic usage, procedural data including the number of office-based double balloon dilation procedures performed and dilation diameter, complications, and subjective outcomes at 2 weeks post-dilation were recorded.
resultsNineteen office-based double balloon dilations to 24 mm (12 + 12-mm balloons) were performed in seven patients (mean age: 65.3 years, 57.1% female). Indications for dilation were varied. Two (28.6%) patients had a history of oropharyngeal cancer treated with radiation therapy. No patients were post-laryngectomy. The majority (85.7%) of patients underwent at least one prior in-office transnasal single balloon dilation. Two (28.6%) patients required a pre-procedure anxiolytic. One complication occurred involving post-procedure epistaxis that resolved with topical oxymetazoline application. No esophageal lacerations or perforations were encountered. No procedures required early termination due to poor patient tolerance. The majority (71.4%) of patients reported subjective improvement in dysphagia symptoms at 2-week follow-up.
conclusionDouble balloon dilation of the PES is feasible in unsedated patients in the office setting. LEVEL OF EVIDENCE: 4:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.